N-[2-chloro-5-(2-oxo-9-pyrazol-1-ylbenzo[h][1,6]naphthyridin-1-yl)phenyl]acetamide
C23H16ClN5O2 — CID 129048369
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[2-chloro-5-(2-oxo-9-pyrazol-1-ylbenzo[h][1,6]naphthyridin-1-yl)phenyl]acetamide
N-[2-chloro-5-(2-oxo-9-pyrazol-1-ylbenzo[h][1,6]naphthyridin-1-yl)phenyl]acetamide (PubChem CID 129048369) has the molecular formula C23H16ClN5O2 and a molecular weight of 429.87 g/mol. Its IUPAC name is N-[2-chloro-5-(2-oxo-9-pyrazol-1-ylbenzo[h][1,6]naphthyridin-1-yl)phenyl]acetamide.
Molecular Properties
| Compound Name | N-[2-chloro-5-(2-oxo-9-pyrazol-1-ylbenzo[h][1,6]naphthyridin-1-yl)phenyl]acetamide |
|---|---|
| PubChem CID | 129048369 |
| Molecular Formula | C23H16ClN5O2 |
| Molecular Weight | 429.87 g/mol |
| Exact Mass | 429.10 |
| IUPAC Name | N-[2-chloro-5-(2-oxo-9-pyrazol-1-ylbenzo[h][1,6]naphthyridin-1-yl)phenyl]acetamide |
| SMILES | CC(=O)Nc1cc(-n2c(=O)ccc3cnc4ccc(-n5cccn5)cc4c32)ccc1Cl |
| InChI | InChI=1S/C23H16ClN5O2/c1-14(30)27-21-12-17(4-6-19(21)24)29-22(31)8-3-15-13-25-20-7-5-16(11-18(20)23(15)29)28-10-2-9-26-28/h2-13H,1H3,(H,27,30) |
| InChIKey | HIVHGFJCMZOYNF-UHFFFAOYSA-N |
| XLogP | 4.34 |
| TPSA | 81.81 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 429.87 |
| LogP ≤ 5 | 4.34 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Polycyclic_aromatic_hydrocarbon_3', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 129048369 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.